Positive 30-Day Results in Medtronic's CoreValve Direct Aortic Study

Today Medtronic (NYSE: MDT) announced the 30-day results from its CoreValve ADVANCE Direct Aortic (DA) Study at the 29th Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS 2014) in Milan. The results were "exceptional," showing low rates of all-cause mortality, stroke (0% disabling stroke), and paravalvular leak.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news